AFMD Affimed Therapeutics: Forward P/S Multiple
Affimed develops innovative cancer treatment methods by activating innate immunity. The expected price-to-sales ratio reflects market expectations, where 3.10 is the current level of the metric. The business is not subject to seasonality or macroeconomic downturns. However, the share price remains sensitive to lymphoma treatment successes and R&D spending rates, despite a stable cash reserve.
Analytical breakdowns for Affimed
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
- financial results and valuation multiples details:
AFMD - Net Profit|Projected Future Earnings Affimed|AFMD - Market Cap to Net Income|Future Price to Earnings Affimed N.V.|AFMD - Price/Earnings to Growth Multiple|EV/EBITDA Multiple AFMD|AFMD - Operating profit before amortization|Earnings per share for the last twelve months Affimed|AFMD - Earnings per one share for the last 12 months|Quarterly EPS earnings growth affimed.com|AFMD - Earnings per share increase in current year|Earnings growth forecast for next year Affimed
- sales volume and revenue information:
Analysis of all company metrics:Affimed Therapeutics AFMD
Affimed monetizes innovations in innate immune activation to combat oncology, where future revenues depend on the commercialization of killer cell activator drugs. The current value of 3.10 reflects the ratio of the company's market capitalization to expected sales, allowing the future P/S multiple to assess the extent to which investor expectations are inflated relative to actual revenue growth rates.
Competitor analysis
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA - Forward P/S Multiple|PTGX: Forward P/S Multiple|Future Price to Revenue IMVT (immunovant.com)|KNSA (Kiniksa) - Forward P/S Multiple|Grifols SA - Future Price to Revenue|Forward P/S Multiple ADPT|Market Cap to Expected Sales Ratio Celldex Corp|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|BCRX - Forward Price-to-Revenue Multiple|Vera Therapeutics - Forward P/S Multiple|Market Cap to Future Revenue Ratio Dianthus Therapeutics Inc|PHVS: Forward P/S Multiple|Market Cap to Projected Revenue ABCL|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|Forward P/S Multiple precigen.com|Forward P/S Multiple PHAR|NKTR: Future Price to Revenue|Price-to-Projected Revenue Ratio Upstream Bio Corp UPB|ZBIO - Forward Price-to-Revenue Multiple|Immunome, Inc. - Forward P/S Multiple|GOSS (gossamerbio.com) - Market Cap to Projected Revenue|KalVista Pharmaceuticals, Inc. (KALV) - Price-to-Projected Revenue Ratio|Future Price to Revenue SEPN (Septerna, Inc.)|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|SVRA: Forward Price to Sales|Forward P/S Multiple RIGL|Forward P/S Multiple anaptysbio.com (ANAB)|Price-to-Projected Revenue Ratio Astria Therapeutics, Inc. ATXS|Forward Price to Sales ENGN|RAPT - Price-to-Projected Revenue Ratio|Aerovate Therapeutics Inc (JBIO) - Forward Price-to-Revenue Multiple|ACRS: Forward P/S Multiple|kyvernatx.com (KYTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TLSA|CABA: Forward Price to Sales|Forward P/S Multiple VTYX|Market Cap to Expected Sales Ratio Theratechnologies, Inc|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|ELDN - Forward Price-to-Revenue Multiple|AGEN - Price-to-Projected Revenue Ratio|Climb Bio Inc. (CLYM) - Forward Price-to-Revenue Multiple|ZURA (Zura Bio Limited) - Forward Price-to-Revenue Multiple|aTyr Pharmaceuticals (ATYR) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Adagene Inc|Market Cap to Projected Revenue IMA (Ikena Oncology, Inc.)|Forward P/S Multiple STTK|EQ - Market Cap to Future Revenue Ratio|Forward P/S Multiple CNTB (Connect Biopharma Holdings Limited)|Forward P/S Multiple Immunic Therapeutics IMUX|Atara Biotherapeutics Inc - Forward P/S Multiple|Future Price to Revenue IFRX|XFOR: Forward P/S Multiple|Future Price to Revenue ACET (Adicet Bio, Inc.)|CELU (Celularity Inc) - Forward P/S Multiple|INmune Bio Corporation (INMB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Barinthus Biotherapeutics (BRNS)|Forward Price-to-Revenue Multiple kezarlifesciences.com KZR|Forward P/S Multiple SABS (SAB Biotherapeutics, Inc.)|Akari Therapeutics PLC (AKTX) - Market Cap to Future Revenue Ratio|Enlivex Therapeutics, Ltd. - Forward P/S Multiple|QTTB (Q32 Bio Inc.) - Market Cap to Projected Revenue|GOVX: Forward P/S Multiple|edesabiotech.com (EDSA) - Forward P/S Multiple|IBIO (iBio) - Forward P/S Multiple|Carisma Tx - Future Price to Revenue|Price-to-Projected Revenue Ratio XTL Biopharmaceuticals, Ltd. (XTLB)|Forward Price-to-Revenue Multiple boltbio.com BOLT|Forward P/S Multiple HCWB (HCW Biologics)|APVO: Market Cap to Projected Revenue|AIM - Price-to-Projected Revenue Ratio|Future Price to Revenue ADTX|GRI: Forward P/S Multiple|XORTX Corp - Forward Price to Sales|HIND (Vyome Holdings Inc) - Forward P/S Multiple|Forward P/S Multiple revbiosciences.com|Price-to-Projected Revenue Ratio Indaptus Therapeutics, Inc. (INDP)|SCNI (Scinai Immunotherapeutics Ltd) - Forward Price to Sales|Price-to-Projected Revenue Ratio CalciMedica CALI|ALLK - Forward Price-to-Revenue Multiple|HOOKIPA - Forward P/S Multiple|IGMS - Forward P/S Multiple|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Inc - Forward Price to Sales|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Third Harmonic Bio Inc (THRD) - Market Cap to Expected Sales Ratio
